Biomarkers to predict no-reflow after opening the heart’s artery in STEMI patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In STEMI patients treated with primary PCI, microvascular no-reflow can worsen outcomes. The study will measure immune-inflammatory indices (like SII) and metabolic indexes (such as TyG and UHR) to see if these markers together can predict no-reflow early. It is observational and focuses on risk stratification to support clinical decisions. Eligible participants are adults with STEMI presenting within 12 hours of symptom onset undergoing PCI. The research is conducted at Sohag University and does not involve an intervention beyond biomarker assessment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years old.
* Both sexes.
* Diagnosis of ST-segment elevation myocardial infarction (STEMI) according to current ESC/ACC guidelines.
* Presentation within 12 hours of symptom onset.
* Undergoing primary percutaneous coronary intervention (PCI) as the reperfusion strategy.

Exclusion Criteria:

* Active infection or sepsis.
* Chronic inflammatory or autoimmune diseases.
* Hematological disorders.
* Active malignancy.
* Severe liver disease.
* End-stage renal disease requires dialysis.
* Previous coronary artery bypass graft surgery (CABG).
* Current use of chronic corticosteroid or immunosuppressive therapy.

Where it's running

• Sohag University
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Remon S Adly, MD
• Email: remonsaleh@yahoo.com
• Phone: 00201221878986

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thrombus removal during PCI after thrombolysis for STEMI

  This trial will test whether removing clots during PCI improves outcomes for people with STEMI who received thrombolysis and have a high thrombus burden.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT06654453

• FAST-guided PCI in STEMI with Multivessel Disease

  This trial tests whether using the FAST technique during PCI in STEMI patients with multivessel disease improves outcomes compared with standard treatment.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT05669222

• Using ischemic postconditioning to improve outcomes in heart attack patients

  This study is testing if a new method called ischemic postconditioning can help heart attack patients recover better and reduce the risk of heart failure after treatment.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT03787745

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Using cardiac MRI and AI to predict outcomes after STEMI

  This project will try to use routine cardiac MRI scans plus AI to see if imaging features can predict long-term outcomes in people who had a STEMI treated with primary PCI.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07072858

• Using beta-blockers for heart attack patients in intensive care

  This study is testing if the heart medication metoprolol can help heart attack patients in intensive care feel better and avoid worsening their condition.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT06967194

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.